Even premature babies carry anti-viral antibodies transferred from the mother, researchers at Karolinska Institutet in Sweden report in a paper on maternal antibodies in newborns, published in the journal Nature Medicine. The results could change the approach to infection sensitivity in newborns.
Stockholm/Sweden — Antibodies are transferred from the mother’s blood to the fetus that give the newborn passive defence against infection. Since most of this process takes place during the third trimester of the pregnancy, doctors have regarded very premature babies as being unprotected by such maternal antibodies.However, now that the total repertoire of maternal anti-viral antibodies has been analysed in neonates by researchers at Karolinska Institutet and Karolinska University Hospital, another picture is emerging.
The scientists saw that babies born as early as in week 24 also have maternal antibodies, which surprised them, says corresponding author Dr. Petter Brodin, physician and researcher at the Scilifelab and the Department of Women’s and Children’s Health, Karolinska Institutet. The study comprised 78 mother-child pairs. 32 of the babies were very premature (born before week 30) and 46 were full-term. The analysis show that the repertoire of maternal antibodies was the same in both groups.
Brodin hopes that this makes scientists reconsider some preconceived ideas about the neonate immune system and infection sensitivity so that they can take even better care of newborns. Premature babies could be especially sensitive to infection, but that is not because they lack maternal antibodies. Doctors should concentrate more on other possible causes, maybe like their having underdeveloped lung function or weaker skin barriers, he explained.
Newly Developed Method for Analysis
The study was conducted using a newly developed method for simultaneously analysing the presence of antibodies against all the viruses that can infect humans (with the exception of the Zika virus, which was identified later). The method is developed by US researchers and is based on a so-called bacteriophage display, a technique awarded with the 2018 Nobel Prize in Chemistry.
Briefly, it is based on the ability to make viral particles called bacteriophages display a specific surface protein. In this case, all in all the bacteriophage library displayed over 93,000 different peptides, short-chain proteins, from over 206 species of virus and over 1 000 different strains. The library is mixed with the blood plasma to be tested. Any antibodies in the plasma sample bind with the bacteriophages and can then be detected by the researchers.
The analysis was conducted on samples taken at birth and during the newborns’ first, fourth and twelfth week. The researchers found that the protection offered by the antibodies lasted different durations depending on the virus. This can suggest that their transfer during the fetal stage is regulated rather than random, a possibility the group is now examining further.
Importance for Vaccine Development
The study also shows which parts of the virus proteins that antibodies target, information that is important in the development of vaccines, notes Brodin. If all maternal antibodies target a specific part of a virus protein, that was important to know because then it is that part a vaccine should be based on, he says. He hopes that these results could be used by others to develop better vaccines, such as against the RS virus that causes so much distress for babies every winter.
Publication: “The repertoire of maternal anti-viral antibodies in human newborns”
Christian Pou, Dieudonné Nkulikiyimfura, Ewa Henckel, Axel Olin, Tadepally Lakshmikanth, Jaromir Mikes, Jun Wang, Yang Chen, Anna-Karin Bernhardsson, Anna Gustafsson, Kajsa Bohlin and Petter Brodin. Nature Medicine, online 18 March 2019, doi: 10.1038/s41591-019-0392-8